Dr. Daniel Morgenstern, MBChir
Claim this profileHospital for Sick Children
Studies Neuroblastoma
Studies Brain Tumor
14 reported clinical trials
29 drugs studied
Area of expertise
1Neuroblastoma
Stage IV
MYC positive
ALK positive
2Brain Tumor
MYC positive
BRD4 positive
BRD3 positive
Affiliated Hospitals
Clinical Trials Daniel Morgenstern, MBChir is currently running
Avapritinib
for Pediatric Solid Cancers
This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to \< 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA and/or KIT mutation (including non-synonymous point mutations, insertions, and deletions) or amplification, or DMG-H3K27a who have no available curative treatment options. This is a single-arm trial in which all participants will receive avapritinib. The study consists of 2 parts: dose confirmation, safety, and PK (Part 1) and initial efficacy, safety, and PK at the Part 2 recommended dose (Part 2).
Recruiting1 award Phase 1 & 2
Chemotherapy
for Wilms Tumor
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Recruiting1 award Phase 212 criteria
More about Daniel Morgenstern, MBChir
Clinical Trial Related3 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Daniel Morgenstern, MBChir has experience with
- CLR 131
- Lorlatinib
- Cyclophosphamide
- Dinutuximab
- Tissue Sample Collection
- Blood Sample Collection
Breakdown of trials Daniel Morgenstern, MBChir has run
Neuroblastoma
- Magrolimab + Dinutuximab for Relapsed Neuroblastoma and Osteosarcoma
- CLR 131 for Pediatric Cancer
- Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
Brain Tumor
Solid Tumors
Tumors
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Morgenstern, MBChir specialize in?
Daniel Morgenstern, MBChir focuses on Neuroblastoma and Brain Tumor. In particular, much of their work with Neuroblastoma has involved Stage IV patients, or patients who are MYC positive.
Is Daniel Morgenstern, MBChir currently recruiting for clinical trials?
Yes, Daniel Morgenstern, MBChir is currently recruiting for 5 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Daniel Morgenstern, MBChir has studied deeply?
Yes, Daniel Morgenstern, MBChir has studied treatments such as CLR 131, Lorlatinib, Cyclophosphamide.
What is the best way to schedule an appointment with Daniel Morgenstern, MBChir?
Apply for one of the trials that Daniel Morgenstern, MBChir is conducting.
What is the office address of Daniel Morgenstern, MBChir?
The office of Daniel Morgenstern, MBChir is located at: Hospital for Sick Children, Toronto, Ontario M5G 1X8 Canada. This is the address for their practice at the Hospital for Sick Children.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.